Profusa, Inc. (NASDAQ:PFSA – Get Free Report) saw a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 77,845 shares, a drop of 51.5% from the September 30th total of 160,653 shares. Based on an average daily volume of 645,641 shares, the short-interest ratio is presently 0.1 days. Approximately 15.1% of the shares of the stock are sold short.
Insider Activity at Profusa
In other news, major shareholder Financial Lp Hrt sold 10,602 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $3.56, for a total transaction of $37,743.12. Following the completion of the transaction, the insider owned 18,549 shares of the company’s stock, valued at approximately $66,034.44. The trade was a 36.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 15.00% of the company’s stock.
Wall Street Analyst Weigh In
Several brokerages have commented on PFSA. Wall Street Zen raised Profusa to a “sell” rating in a research note on Saturday, August 22nd. Weiss Ratings upgraded shares of Profusa from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Profusa currently has a consensus rating of “Sell”.
Read Our Latest Stock Analysis on PFSA
Profusa Stock Down 9.2%
Shares of PFSA stock traded down $0.07 during mid-day trading on Friday, reaching $0.70. 161,331 shares of the stock traded hands, compared to its average volume of 2,742,092. The stock’s fifty day simple moving average is $2.07 and its two-hundred day simple moving average is $100.73. Profusa has a 1-year low of $0.69 and a 1-year high of $1,962.75. The company has a market cap of $427,061.00, a price-to-earnings ratio of -0.00 and a beta of 0.53.
Profusa (NASDAQ:PFSA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($151.80) earnings per share (EPS) for the quarter.
About Profusa
Profusa, Inc is a biotechnology and medical-device company focused on developing implantable biosensors designed to continuously monitor biochemical conditions inside the body. Its technology is intended to provide real-time health data without requiring repeated blood draws or external sampling.
The company’s biosensors are designed to be placed under the skin and remain in the body while communicating measurements to an external reader or connected device. Profusa has developed platforms intended to monitor markers such as tissue oxygen levels, with potential applications in areas including peripheral artery disease, wound care, chronic disease management and clinical research.
Profusa’s technology combines a small, injectable hydrogel sensor with optical detection and wireless data transmission.
See Also
- Five stocks we like better than Profusa
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
- The Factories Behind AI Servers Just Raised Their Outlooks—3 Contract Manufacturers to Watch
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
